SCHEMBL3140455

SCHEMBL3140455

Nc1ncccc1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.63
ADORA2A P29274 2/20 0.52
ADORA1 P30542 2/20 0.52
IKBKB O14920 1/20 0.48
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
NPY5R Q15761 1/20 0.45
BRD4 O60885 1/20 0.44
RIPK1 Q13546 1/20 0.44
TGFBR1 P36897 1/20 0.44
SCN2A Q99250 1/20 0.44
CKS1B P61024 1/20 0.44
SKP2 Q13309 1/20 0.44
HRH1 P35367 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
XDH P47989 1/20 0.43
NOS3 P29474 1/20 0.43
NOS2 P35228 1/20 0.43
MAOB P27338 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15394275 0.84 MAP4K4 (0.63) MAP4K4ADORA2AADORA1NOS3NOS2
SCHEMBL29888283 0.81 MKNK1 (0.54) MAP4K4NPY5RRIPK1TLR7MKNK1
SCHEMBL15730622 0.81 PDE2A (0.49) ADORA2AADORA1IKBKBNPY5RBRD4
SCHEMBL623788 0.81 TNK2 (0.51) MAP4K4ADORA2ARIPK1MKNK1MKNK2
SCHEMBL28024466 0.80 ADORA2A (0.49) MAP4K4ADORA2AADORA1IKBKBBRD4
SCHEMBL27827780 0.79 KMO (0.54) ADORA2AADORA1XDHCYP1A2CYP3A4
SCHEMBL18854065 0.78 ALDH1A1 (0.46) ADORA2AADORA1NPY5RTGFBR1SCN2A
SCHEMBL31606903 0.77 ADORA2A (0.51) ADORA2AADORA1IKBKBTSHRMAPK1
SCHEMBL28913992 0.77 MAP4K4 (0.54) MAP4K4TGFBR1MKNK1MKNK2
SCHEMBL901856 0.77 NOS3 (0.51) MAP4K4TSHRMAPK1RIPK1TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013006738-A1 COMPOUNDS FOR THE TREATMENT OF HIV GILEAD SCIENCES, INC. (US) 2013-01-10 WO disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 US disclosed
EP-1989201-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2008-11-12 EP disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE PIK3CA, PIK3CD, PIK3CB MAP4K4 390/4885ADORA2A 914/4885ADORA1 1744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.